High Impact
As coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.
The artificial intelligence (AI) wave sweeping the biopharmaceutical industry is showing no signs of abating. We’ve chronicled the rising tide of AI-driven advancements in medicine and healthcare—bridging hype and reality—right here on a couple of occasions in the last year or so. As various coverage in Pharmaceutical Executive’s March issue attests yet again, the connections and permutations are seemingly everywhere, and only growing. Today, AI is impacting, on some level or another, all, if not most of the topics, trends, strategies, functions, etc., that we report on, no matter how diverse the subject matter.
March content in Pharm Exec capturing such tie-ins include:
- Virtual reality’s emergence as a go-to tool for pharma sales reps, enabling deeper understanding and interaction during visits in the field, as well as redefining at-home treatment and care.
- Viewing AI’s internal role in pharma, and its implementation, not just as an auxiliary tool, but as part of the workforce—basically akin to “considering a robot as part of your talent pool.”
- The benefits of AI-enabled benchmarking in curing the ills of traditional approaches in measuring brand performance.
- Future HCP/patient engagement is about creating the right blend of data-driven insights and human expertise.
AI’s ascension and attention are uniquely intertwined at the moment. As a trusted source for pharma insights, we can’t ignore that dynamic. Nor should we. This is an area that demands continued examination and ongoing perspective checks, as the potential value-adds from AI for the industry unfold in real-time.
Thanks for reading.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
